DBDaniel J. Baker

Daniel J. Baker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel J. Baker has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Carl H. June

    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States

    5 shared publications
  • A.M. Mendelsohn

    Janssen Research & Development, LLC, Spring House, PA

    1 shared publication
  • Alexander A. Soukas

    Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA

    1 shared publication
  • Armen Yerevanian

    Department of Medicine, Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital , Boston, MA 02114

    1 shared publication
  • Bruce L Levine

    Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    1 shared publication
  • Chenglong Han

    Janssen Research & Development, LLC, Spring House, USA

    1 shared publication

Latest Publications

  • Open Access

    Reductive death is averted by an ancient metabolic switch

    by Fasih M. Ahsan, Jen F. Rotti, Armen I. Yerevanian, Sinclair W. Emans, Nicole L. Stuhr, Jose A. Aceves-Salvador, Wei Wang, Daniel J. Baker, Dimitra Pouli, Owen S. Skinner, et al.

    SUMMARY: Biguanides, including metformin, the world’s most prescribed oral hypoglycemic, extend health-span and lifespan in vertebrates and invertebrates. Given the widespread use and apparent safety of metformin, it is assumed that its effects are not associated with toxicity, except when in marked excess. Here we determine that accumulation of damaging reducing equivalents is an unanticipated toxicity associated with biguanides, the defense against which requires post-transcriptional protection of de novo fatty acid biosynthesis. We demonstrate that biguanide treatment during impaired fatty acid biosynthesis drives NADPH toxicity, leading to catastrophic elevation of NADH/GSH reducing equivalents and accelerated death across metazoans. Multiple NADPH-generating interventions require fatty acid biosynthesis to prevent markedly shortened survival, indicating that this defense mechanism is broadly leveraged. We propose that fatty acid biosynthesis is a tunable rheostat which can minimize biguanide-induced reductive stress whilst maximizing its pro-longevity outcomes and serve as an exploitable vulnerability in reductive stress sensitive cancers. HIGHLIGHTS: Biguanides inhibit cytosolic mRNA translation to extend lifespan in C. elegans . Fatty acid synthesis is translationally protected by eIF3 complex subunits. pod-2 / fasn-1 inactivation amplifies biguanide-induced reductive stress and death. NADPH-generating insults require fatty acid synthesis to buffer reductive stress.

  • Open Access

    Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cells

    by Nils W. Engel, Israel Steinfeld, Daniel Ryan, Kusala Anupindi, Samuel Kim, Nils Wellhausen, Linhui Chen, Katherine Wilkins, Daniel J. Baker, Philipp C. Rommel, et al.

    Genome-editing technologies have enabled the clinical development of allogeneic cellular therapies, yet the optimal gene-editing modality for multiplex editing of therapeutic T cell product manufacturing remains elusive. In this study, we conducted a comprehensive comparison of CRISPR/Cas9 nuclease and adenine base editor (ABE) technologies in generating allogeneic chimeric antigen receptor (CAR) T cells, utilizing extensive in vitro and in vivo analyses. Both methods achieved high editing efficiencies across four target genes, critical for mitigating graft-versus-host disease and allograft rejection: TRAC or CD3E , B2M , CIITA , and PVR . Notably, ABE demonstrated higher manufacturing yields and distinct off-target profiles compared to Cas9, with translocations observed exclusively in Cas9-edited products. Functionally, ABE-edited CAR T cells exhibited superior in vitro effector functions under continuous antigen stimulation, including enhanced proliferative capacity and increased surface CAR expression. Transcriptomic analysis revealed that ABE editing resulted in reduced activation of p53 and DNA damage response pathways at baseline, along with sustained activation of metabolic pathways during antigen stress. Consistently, Assay for Transposase-Accessible Chromatin using sequencing data indicated that Cas9-edited, but not ABE-edited, CAR T cells showed enrichment of chromatin accessibility peaks associated with double-strand break repair and DNA damage response pathways. In a preclinical leukemia model, ABE-edited CAR T cells demonstrated improved tumor control and extended overall survival compared to their Cas9-edited counterparts. Collectively, these findings position ABE as superior to Cas9 nucleases for multiplex gene editing of therapeutic T cells.


  • Top Cited Papers

    CAR T therapy beyond cancer: the evolution of a living drug

    by Daniel J. Baker, Zoltan Arany, Joseph A. Baur, Jonathan A. Epstein, Carl H. June

    Engineering a patient’s own T cells to selectively target and eliminate tumour cells has cured patients with untreatable haematologic cancers. These results have energized the field to apply chimaeric antigen receptor (CAR) T therapy throughout oncology. However, evidence from clinical and preclinical studies underscores the potential of CAR T therapy beyond oncology in treating autoimmunity, chronic infections, cardiac fibrosis, senescence-associated disease and other conditions. Concurrently, the deployment of new technologies and platforms provides further opportunity for the application of CAR T therapy to noncancerous pathologies. Here we review the rationale behind CAR T therapy, current challenges faced in oncology, a synopsis of preliminary reports in noncancerous diseases, and a discussion of relevant emerging technologies. We examine potential applications for this therapy in a wide range of contexts. Last, we highlight concerns regarding specificity and safety and outline the path forward for CAR T therapy beyond cancer.


  • CAR T therapy extends its reach to autoimmune diseases

    by Daniel J. Baker, Carl H. June


  • AB0491 Fatigue is an independent variable predicting physical function and DAS-28 remission for patients with rheumatoid arthritis treated with intravenously administered golimumab: results from phase 3, placebo controlled clinical trial

    by R. Westhovens, M.E. Weinblatt, C. Han, T. Gathany, L. Kim, M. Mack, J. Lu, D. Baker, A.M. Mendelsohn, C.O. Bingham

    Objectives To evaluate the association of fatigue with physical function and disease activity in patients with rheumatoid arthritis (RA), and the impact of treatment with intravenously administered golimumab (GLM) on fatigue using data from the Phase III clinical trial GO-FURTHER. Methods GO-FURTHER was a multicenter, randomized, placebo-controlled study. Adult patients with active RA despite MTX therapy were randomized to placebo + MTX (placebo group) or GLM 2mg/kg plus MTX (GLM group) at week 0, 2, and every 8 week thereafter. Patients in placebo group with Results At baseline, mean (SD) FACIT-Fatigue score was 25.5 (10.54), indicating significant fatigue. Significant correlations of FACIT-Fatigue with HAQ (r=-0.62, pConclusions RA patients inadequately responsive to MTX experienced severe fatigue. Fatigue was a significant independent predictor of physical function and disease activity in patients with RA. Treatment with intravenously administered GLM significantly improved clinical symptoms of fatigue in patients with RA inadequately responsive to MTX. Disclosure of Interest R. Westhovens Grant/Research support from: Investigators for Janssen Research & Development, LLC sponsored clinical study, M. Weinblatt Grant/Research support from: Investigators for Janssen Research & Development, LLC sponsored clinical study, C. Han Employee of: Johnson & Johnson Pharmaceutical Services, LLC, T. Gathany Employee of: Johnson & Johnson Pharmaceutical Services, LLC, L. Kim Employee of: Janssen Research & Development, LLC, M. Mack Employee of: Janssen Research & Development, LLC, J. Lu Employee of: Janssen Research & Development, LLC, D. Baker Employee of: Janssen Research & Development, LLC, A. Mendelsohn Employee of: Janssen Research & Development, LLC, C. Bingham III Grant/Research support from: Investigators for Janssen Research & Development, LLC sponsored clinical study